Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 3/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643024 | 0.86 | PLK1 (0.51) | PLK1ELANEPRTN3SUCNR1ACAT1 | |
| SCHEMBL15484626 | 0.79 | PLK1 (0.52) | PLK1ELANEPRTN3SUCNR1ACAT1 | |
| SCHEMBL643023 | 0.79 | PLK1 (0.52) | PLK1ELANEPRTN3SUCNR1ACAT1 | |
| SCHEMBL642937 | 0.72 | PLK1 (0.63) | PLK1SUCNR1ACAT1RARBNR1H4 | |
| SCHEMBL644422 | 0.72 | PLK1 (0.63) | PLK1SUCNR1ACAT1RARBNR1H4 | |
| SCHEMBL644677 | 0.70 | PLK1 (0.61) | PLK1SUCNR1ACAT1RARBNR1H4 | |
| SCHEMBL642216 | 0.70 | PLK1 (0.60) | PLK1SUCNR1ACAT1RARBNR1H4 | |
| SCHEMBL26671910 | 0.69 | PLK1 (0.67) | PLK1ACAT1NR1H4BCHEACHE | |
| SCHEMBL641466 | 0.69 | PLK1 (0.57) | PLK1SUCNR1RARBNR1H4MAPT | |
| SCHEMBL643796 | 0.68 | PLK1 (0.58) | PLK1SUCNR1ACAT1RARBNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | PLK1 1883/4885ELANE 509/4885PRTN3 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.